Patents by Inventor Cynthia Sung
Cynthia Sung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11219616Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: December 23, 2019Date of Patent: January 11, 2022Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20200338050Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: December 23, 2019Publication date: October 29, 2020Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 10517854Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.Type: GrantFiled: September 18, 2017Date of Patent: December 31, 2019Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20180064693Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.Type: ApplicationFiled: September 18, 2017Publication date: March 8, 2018Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
-
Patent number: 9763921Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: March 14, 2014Date of Patent: September 19, 2017Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of SingaporeInventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20160158146Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.Type: ApplicationFiled: February 17, 2016Publication date: June 9, 2016Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
-
Publication number: 20160030403Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW
-
Publication number: 20100272777Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.Type: ApplicationFiled: December 28, 2009Publication date: October 28, 2010Applicants: Department of HealthInventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
-
Patent number: 7658364Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.Type: GrantFiled: March 14, 2002Date of Patent: February 9, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A. Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
-
Publication number: 20070190111Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.Type: ApplicationFiled: April 24, 2007Publication date: August 16, 2007Applicant: Govemment of the U.S.A, represented by the Secretary, Department. of Health and HumanInventors: Michael Robinson, Karl Csaky, Robert Nussenblatt, Janine Smith, Peng Yuan, Cynthia Sung, Matthew Fronheiser, Hyuncheol Kim
-
Publication number: 20040180075Abstract: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.Type: ApplicationFiled: May 3, 2004Publication date: September 16, 2004Inventors: Michael R. Robinson, Karl G. Csaky, Robert B. Nussenblatt, Janine A Smith, Peng Yuan, Cynthia Sung, Matthew P. Fronheiser, Hyuncheol Kim
-
Patent number: 6713081Abstract: Ocular implant devices for the delivery of a therapeutic agent to an eye in a controlled and sustained manner. Dual mode and single mode drug delivery devices are illustrated and described. Implants suitable for subconjunctival placement are described. Implants suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices that are presented herein.Type: GrantFiled: March 15, 2001Date of Patent: March 30, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Robinson, Karl G. Csaky, Peng Yuan, Cynthia Sung, Robert B. Nussenblatt, Janine A. Smith
-
Publication number: 20030175324Abstract: Ocular implant devices for the delivery of a therapeutic agent to an eye in a controlled and sustained manner. Dual mode and single mode drug delivery devices are illustrated and described. Implants suitable for subconjunctival placement are described. Implants suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices that are presented herein.Type: ApplicationFiled: March 15, 2001Publication date: September 18, 2003Inventors: Michael R. Robinson, Karl G. Csaky, Peng Yuan, Cynthia Sung, Robert B. Nussenblatt, Janine A. Smith
-
Patent number: 4910015Abstract: A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane is described. These materials form hydrogel networks having very high partition coefficients for selected pharmaceuticals and are suitable for controlled drug release and water purification.Type: GrantFiled: October 19, 1987Date of Patent: March 20, 1990Assignee: Massachusetts Institute of TechnologyInventors: Cynthia Sung, Edward W. Merrill
-
Patent number: 4906465Abstract: A crosslinked polymer network comprising the reaction product of a polyethylene oxide and a polyglycidoxypropylsiloxane is described. These materials demonstrate low in vivo platelet retention as well as a low thrombogenicity. As such, they can provide antithrombogenic properties to blood contacting devices such as catheters, artificial hearts, ventricular grafts and cardiovascular suture.Type: GrantFiled: March 16, 1988Date of Patent: March 6, 1990Assignee: Massachusetts Institute of TechnologyInventors: Elliot L. Chaikof, Cynthia Sung, Edward W. Merrill